Contact | Print version | PDF version | Send article | RSS feed

Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients

25 Feb 2008 - Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland.
 
The test, known as CRS7, is the first clinical test capable of predicting the likelihood of an HCV patient's risk of progressing to liver fibrosis and cirrhosis. According to the company, the availability of this test will substantially aid in the clinical management of HCV patients by ensuring they receive accurate, personalised treatment. The test has been clinically validated through multi-centre studies in North America.